William Stilley, Adial Pharmaceuticals CEO
July 20, 2022 01:18 PM EDTUpdated 01:49 PM
R&D

Mi­cro­cap biotech's shares crater on a PhI­II fail­ure for heavy drink­ing drug

John Carroll

Editor & Founder

Shares of mi­cro­cap biotech Adi­al Phar­ma­ceu­ti­cals cratered Wednes­day af­ter the com­pa­ny con­ced­ed its ex­per­i­men­tal ther­a­py for heavy drinkers had failed the pri­ma­ry end­point in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times